Executives On The Move: Comings And Goings This Week At Sosei And Shire, Plus An Upcoming Departure At Ferring
Sosei Group selects a new EVP, CFO and Rare Diseases VP departs Shire for Blueprint Medicines. At Ferring Pharmaceuticals, COO makes known plans to step down.
You may also be interested in...
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.